NO20015992L - Fremgangsmåte for inhibering av amyloidprotein-aggregering og billeddannelse av amyloidavleiring ved bruk av isoindolin-derivater - Google Patents
Fremgangsmåte for inhibering av amyloidprotein-aggregering og billeddannelse av amyloidavleiring ved bruk av isoindolin-derivaterInfo
- Publication number
- NO20015992L NO20015992L NO20015992A NO20015992A NO20015992L NO 20015992 L NO20015992 L NO 20015992L NO 20015992 A NO20015992 A NO 20015992A NO 20015992 A NO20015992 A NO 20015992A NO 20015992 L NO20015992 L NO 20015992L
- Authority
- NO
- Norway
- Prior art keywords
- amyloid
- depletion
- imaging
- protein aggregation
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Radiology & Medical Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13854399P | 1999-06-10 | 1999-06-10 | |
| PCT/US2000/015073 WO2000076969A1 (en) | 1999-06-10 | 2000-05-31 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20015992D0 NO20015992D0 (no) | 2001-12-07 |
| NO20015992L true NO20015992L (no) | 2002-02-06 |
Family
ID=22482508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20015992A NO20015992L (no) | 1999-06-10 | 2001-12-07 | Fremgangsmåte for inhibering av amyloidprotein-aggregering og billeddannelse av amyloidavleiring ved bruk av isoindolin-derivater |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP1192131B1 (zh) |
| JP (1) | JP2003502313A (zh) |
| KR (1) | KR20020012266A (zh) |
| CN (1) | CN1156445C (zh) |
| AP (1) | AP1398A (zh) |
| AT (1) | ATE272623T1 (zh) |
| AU (1) | AU777747B2 (zh) |
| BG (1) | BG106291A (zh) |
| BR (1) | BR0011446A (zh) |
| CA (1) | CA2373394A1 (zh) |
| CR (1) | CR6530A (zh) |
| CZ (1) | CZ20014366A3 (zh) |
| DE (1) | DE60012742T2 (zh) |
| DK (1) | DK1192131T3 (zh) |
| DZ (1) | DZ3262A1 (zh) |
| EA (1) | EA004405B1 (zh) |
| EE (1) | EE200100666A (zh) |
| ES (1) | ES2223531T3 (zh) |
| GE (1) | GEP20043407B (zh) |
| HK (1) | HK1046283B (zh) |
| HR (1) | HRP20020027A2 (zh) |
| HU (1) | HUP0201586A2 (zh) |
| IL (1) | IL146455A0 (zh) |
| IS (1) | IS6162A (zh) |
| MA (1) | MA26807A1 (zh) |
| MX (1) | MXPA01011112A (zh) |
| NO (1) | NO20015992L (zh) |
| NZ (1) | NZ515619A (zh) |
| OA (1) | OA11958A (zh) |
| PL (1) | PL352294A1 (zh) |
| PT (1) | PT1192131E (zh) |
| SI (1) | SI1192131T1 (zh) |
| SK (1) | SK17622001A3 (zh) |
| TR (1) | TR200200257T2 (zh) |
| UA (1) | UA64842C2 (zh) |
| WO (1) | WO2000076969A1 (zh) |
| YU (1) | YU86801A (zh) |
| ZA (1) | ZA200109164B (zh) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6972287B1 (en) | 1999-06-10 | 2005-12-06 | Pfizer Inc. | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
| AP2002002387A0 (en) * | 1999-06-10 | 2002-03-31 | Warner Lambert Co | Method of inhibiting amyloid aggregation and imaging amyloid deposits. |
| PE20020394A1 (es) | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
| CA2357450A1 (en) * | 2000-09-29 | 2002-03-29 | Warner-Lambert Company | Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| AR042206A1 (es) * | 2002-11-26 | 2005-06-15 | Novartis Ag | Acidos fenilaceticos y derivados |
| GB2404855A (en) * | 2003-07-07 | 2005-02-16 | Pantherix Ltd | Arylcarboxylic acid derivatives and their therapeutic use |
| AR061623A1 (es) | 2006-06-26 | 2008-09-10 | Novartis Ag | Derivados de acido fenilacetico |
| KR101450356B1 (ko) * | 2006-11-24 | 2014-10-15 | 에이씨 이뮨 에스.에이. | 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체 |
| AU2008215948A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of AD and related conditions |
| PT2307381T (pt) * | 2008-06-09 | 2021-03-15 | Univ Muenchen Ludwig Maximilians | Novas drogas para inibir a agregação de proteínas envolvidas em doenças relacionadas com a agregação de proteínas e/ou doenças neurodegenerativas |
| KR20110113197A (ko) | 2009-02-06 | 2011-10-14 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | 감마 세크레타제 조절제로서의 신규 치환된 비사이클릭 헤테로사이클릭 화합물 |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| EP2427453B1 (en) * | 2009-05-07 | 2013-07-17 | Janssen Pharmaceuticals, Inc. | Substituted indazole and aza-indazole derivatives as gamma secretase modulators |
| CN102482227A (zh) | 2009-07-15 | 2012-05-30 | 杨森制药公司 | 作为γ分泌酶调节剂的取代的三唑和咪唑衍生物 |
| BR112012017442A2 (pt) | 2010-01-15 | 2016-04-19 | Janssen Pharmaceuticals Inc | derivados de triazol bicíclicos substituídos como moduladores de gamma secretase |
| AU2012230348A1 (en) | 2011-03-24 | 2013-08-29 | Cellzome Limited | Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators |
| CN103874702B (zh) | 2011-07-15 | 2015-12-09 | 杨森制药公司 | 作为γ分泌酶调节剂的经取代的吲哚衍生物 |
| BR112014028395B1 (pt) | 2012-05-16 | 2022-02-01 | Janssen Pharmaceuticals, Inc. | Derivados 3,4-di-hidro-2h-pirido[1,2-a]pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer e composição farmacêutica que os compreende |
| AU2013366668B2 (en) | 2012-12-20 | 2017-07-20 | Janssen Pharmaceutica Nv | Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators |
| KR102171710B1 (ko) | 2013-01-17 | 2020-10-30 | 얀센 파마슈티카 엔.브이. | 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체 |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| RU2681537C2 (ru) * | 2014-04-14 | 2019-03-07 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение |
| US11071793B2 (en) * | 2014-08-29 | 2021-07-27 | Chdi Foundation, Inc. | Probes for imaging huntingtin protein |
| CN112250627B (zh) | 2014-10-06 | 2024-02-02 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
| WO2017173274A1 (en) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| RS62670B1 (sr) | 2016-09-30 | 2021-12-31 | Vertex Pharma | Modulator transmembranskog regulatora provodnosti cistične fibroze, farmaceutske kompozicije, metode lečenja i proces izrade modulatora |
| MX2019006637A (es) | 2016-12-09 | 2019-08-21 | Vertex Pharma | Modulador del regulador de conductancia transmembrana de fibrosis quistica composiciones farmaceuticas metodos de tratamiento y proceso para producir el modulador. |
| CN110225753B (zh) * | 2017-01-28 | 2022-12-09 | 金凯(辽宁)生命科技股份有限公司 | 用于制备5-苯氧基-1(3h)异苯并呋喃酮的方法 |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| CA3071278A1 (en) | 2017-08-02 | 2019-02-07 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
| CN109232533A (zh) * | 2017-09-28 | 2019-01-18 | 北京越之康泰生物医药科技有限公司 | 氮杂环类衍生物、其制备方法及其医药用途 |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| MX2020005753A (es) | 2017-12-08 | 2020-08-20 | Vertex Pharma | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| EP4367112A1 (en) | 2021-07-09 | 2024-05-15 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552426A (en) * | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
-
2000
- 2000-05-31 EA EA200101133A patent/EA004405B1/ru not_active IP Right Cessation
- 2000-05-31 DE DE2000612742 patent/DE60012742T2/de not_active Expired - Fee Related
- 2000-05-31 PT PT00938023T patent/PT1192131E/pt unknown
- 2000-05-31 JP JP2001503829A patent/JP2003502313A/ja active Pending
- 2000-05-31 CZ CZ20014366A patent/CZ20014366A3/cs unknown
- 2000-05-31 GE GE4625A patent/GEP20043407B/en unknown
- 2000-05-31 EP EP00938023A patent/EP1192131B1/en not_active Expired - Lifetime
- 2000-05-31 AP APAP/P/2002/002389A patent/AP1398A/en active
- 2000-05-31 TR TR2002/00257T patent/TR200200257T2/xx unknown
- 2000-05-31 DZ DZ003262A patent/DZ3262A1/fr active
- 2000-05-31 UA UA2001117664A patent/UA64842C2/uk unknown
- 2000-05-31 NZ NZ515619A patent/NZ515619A/en unknown
- 2000-05-31 DK DK00938023T patent/DK1192131T3/da active
- 2000-05-31 PL PL00352294A patent/PL352294A1/xx not_active Application Discontinuation
- 2000-05-31 HU HU0201586A patent/HUP0201586A2/hu unknown
- 2000-05-31 BR BR0011446-4A patent/BR0011446A/pt not_active IP Right Cessation
- 2000-05-31 SI SI200030475T patent/SI1192131T1/xx unknown
- 2000-05-31 ES ES00938023T patent/ES2223531T3/es not_active Expired - Lifetime
- 2000-05-31 AU AU53120/00A patent/AU777747B2/en not_active Ceased
- 2000-05-31 EE EEP200100666A patent/EE200100666A/xx unknown
- 2000-05-31 SK SK1762-2001A patent/SK17622001A3/sk unknown
- 2000-05-31 AT AT00938023T patent/ATE272623T1/de not_active IP Right Cessation
- 2000-05-31 YU YU86801A patent/YU86801A/sh unknown
- 2000-05-31 CN CNB008087288A patent/CN1156445C/zh not_active Expired - Fee Related
- 2000-05-31 KR KR1020017015827A patent/KR20020012266A/ko not_active Application Discontinuation
- 2000-05-31 OA OA1200100320A patent/OA11958A/en unknown
- 2000-05-31 MX MXPA01011112A patent/MXPA01011112A/es not_active Application Discontinuation
- 2000-05-31 CA CA002373394A patent/CA2373394A1/en not_active Abandoned
- 2000-05-31 IL IL14645500A patent/IL146455A0/xx unknown
- 2000-05-31 WO PCT/US2000/015073 patent/WO2000076969A1/en not_active Application Discontinuation
-
2001
- 2001-11-06 ZA ZA200109164A patent/ZA200109164B/en unknown
- 2001-11-15 IS IS6162A patent/IS6162A/is unknown
- 2001-12-07 CR CR6530A patent/CR6530A/es not_active Application Discontinuation
- 2001-12-07 NO NO20015992A patent/NO20015992L/no not_active Application Discontinuation
-
2002
- 2002-01-03 MA MA26467A patent/MA26807A1/fr unknown
- 2002-01-09 BG BG106291A patent/BG106291A/bg unknown
- 2002-01-10 HR HR20020027A patent/HRP20020027A2/hr not_active Application Discontinuation
- 2002-10-30 HK HK02107877.1A patent/HK1046283B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20015992L (no) | Fremgangsmåte for inhibering av amyloidprotein-aggregering og billeddannelse av amyloidavleiring ved bruk av isoindolin-derivater | |
| EA200000274A3 (ru) | Способы получения и промежуточные соединения для получения противораковых соединений | |
| EE200100358A (et) | Meetod ja komplekt prioonivalgu ekstraheerimiseks | |
| NO996352L (no) | Kappaagonistforbindelser, farmasøytiske formuleringer og metode for forhindring og behandling av kløe med disse | |
| NO20021412L (no) | Soyamelkeblandinger og fremgangsmåter for fremstilling | |
| NO985484D0 (no) | FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi | |
| NO20015995L (no) | Metode for inhibering av amyloid-protein-aggregering og billeddannelse av amyloid-avleiringer | |
| EA200001234A1 (ru) | Способ проведения платежей и устройство для его реализации | |
| NO20004896D0 (no) | Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav | |
| NO20003070D0 (no) | Substituert tiazolidinderivat, fremgangsmÕte for fremstilling og anvendelse derav | |
| NO20015516L (no) | Preparater og anvendelser av ET743 for behandling av kreft | |
| DE60008820D1 (de) | Bilderzeugungsverfahren und Bilderzeugungsgerät | |
| NO20010464L (no) | FremgangsmÕter og preparater for behandling av gastro- øsofagealt-reflukssyndrom | |
| NO20014528L (no) | Fremgangsmåte for påvisning av megsinprotein og anvendelse av dette | |
| NO20014848D0 (no) | Fremgangsmåte for anvendelse av Emamectin ved behandling av fiskeparasitter | |
| DE60016423D1 (de) | Ätzmethode und plasmabehandlungsmethode | |
| AU5311800A (en) | Rhodanine derivatives for use in a method of inhibiting amyloid protein aggregation and imaging amyloid deposits | |
| NO20012099D0 (no) | Fremgangsmåte for fremstilling av 4-arylpiperidin-3- carbinoler og beslektede forbindelser | |
| NO20020777L (no) | Farmasöytiske preparater inneholdende derivater og fremgangsmåte for fremstilling derav | |
| NO20022984L (no) | Forbindelse og fremgangsmåte for behandling av smerte | |
| NO20022990L (no) | Fremgangsmåte og sammensetning for behandling av smerte | |
| NO20022157D0 (no) | Fremgangsmåte for behandling av medikamentavhengighet | |
| AU6979800A (en) | Device and method for the partial electrochemical treatment of bar-shaped elements | |
| NO20003881D0 (no) | Bibapcitid-baserte farmasøytiske sammensetninger for avbildning og behandling av thromber | |
| NO992217D0 (no) | Biopsikassettenhet og fremgangsmÕte for biopsiprepareringer ved bruk av biopsikassettenheten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |